Surmodics | SRDX - Des Atouts





Des Atouts Changement Date
Abbott USD 86.71B 2.53B 2025-12
Align Technology USD 6.23B 141K 2025-12
Anika Therapeutics USD 189.44M 1.76M 2025-09
Arrowhead Research USD 1.6B 218.89M 2025-12
Artivion USD 857.66M 19.27M 2025-09
Baxter International USD 20.06B 1.01B 2025-12
Boston Scientific USD 43.67B 966M 2025-12
EDAP TMS EUR 61.46M 6.88M 2025-09
Edwards Lifesciences USD 13.27B 216.5M 2025-09
Haemonetics USD 2.49B 48.73M 2025-12
Heron Therapeutics USD 248.95M 16.86M 2025-09
J&J USD 199.21B 6.39B 2025-12
Merit Medical Systems USD 2.69B 54.92M 2025-12
Mesa Laboratories USD 434.85M 4.5M 2025-12
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Option Care Health USD 3.46B 24.08M 2025-12
Stryker USD 47.84B 787M 2025-12
Surmodics USD 178.56M 1.15M 2024-09
Trinity Biotech USD 103.71M 4.08M 2025-09